Claims
- 1. A method of treating BPH in a subject in need of such treatment which method comprises administering to said subject an effective amount of a combination of (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) an α1-adrenergic receptor antagonist, or a pharmaceutically acceptable derivative thereof.
- 3. The method of claim 1 wherein (A) and (B) are administered simultaneously, sequentially or separately.
- 4. The method of claim 1, wherein (B) is selected from terazosin, doxazosin, prazosin, bunazosin, alfuzosin, naftopidil, tamsulosin, silodosin, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2, 3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or a pharmaceutically acceptable derivative thereof.
- 5. The method of claim 4, wherein (B) is doxazosin or a pharmaceutically acceptable derivative thereof.
- 6. The method of claim 4, wherein (B) is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2, 3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof.
- 7. The method of claim 4, wherein (B) is 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)quinazolinone, or a pharmaceutically acceptable derivative thereof.
- 8. A pharmaceutical composition comprising (A) atorvastatin, or a pharmaceutically acceptable derivative thereof, and (B) doxazosin, or a pharmaceutically acceptable derivative thereof.
- 9. A pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof.
- 10. A pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable derivative thereof.
- 11. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) doxazosin or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- 12. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- 13. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- 14. A pharmaceutical composition according to any one of claims 8 to 13, further comprising a pharmaceutically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0221579.6 |
Sep 2002 |
GB |
|
Parent Case Info
[0001] This application claims priority to U.S. Provisional Application No. 60/417,521, filed Oct. 9, 2002, and GB Application No. 0221582.0, filed Sep. 17, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60417521 |
Oct 2002 |
US |